This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with mild Alzheimer's disease.

Inclusion Criteria:

• Diagnosis of Mild Alzheimer's Disease
• Mini-Mental State Examination (MMSE) 20 to 26 at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 6 weeks

Exclusion Criteria:

• Previously participated in an AD vaccine study and received active treatment
• History or presence of an active autoimmune and/or with an acute or chronic inflammation, and/or clinically relevant atopic condition.
• History or presence of seizures and/or cerebrovascular disease.
• Presence of an other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression)